MiNK Therapeutics (INKT) Misses Q2 EPS by 106c

MiNK Therapeutics (NASDAQ: INKT) reported Q2 EPS of ($1.06).

For earnings history and earnings-related data on MiNK Therapeutics (INKT) click here.

You May Also Be Interested In

• Senior Iranian Official To Reuters: Tehran Is Reviewing U.S. Response To Its Proposal To End Hostilities
• Iran's Pezeshkian says country will not surrender to U.S.
• Cracker Barrel (CBRL) Tops Q4 EPS by 89c, Offers Guidance